|Bid||259.75 x 800|
|Ask||260.27 x 800|
|Day's Range||257.00 - 262.63|
|52 Week Range||228.00 - 459.75|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||46.19|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||336.88|
Abiomed’s (ABMD) Impella platform is being featured today at a Washington, D.C., event showcasing innovations in medical technology that improve healthcare for women. Abiomed’s participation supports its Women’s Initiative for Heart Recovery, which provides education and raises awareness of women’s cardiovascular diseases and the opportunity for heart recovery. One young woman who benefited from heart recovery with Impella support is Iman Dorty, who is speaking at today’s event.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Abiomed Inc NASDAQ/NGS:ABMDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ABMD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABMD totaled $7.94 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Medical technology stocks hit record highs last year and are rising thus far in 2019. Two of the fastest growing among them have tacked on double-digit earnings growth for several years.
Uber shares are popping today on word analysts practically all love the stock. But turns out, it's not the only stock showered with "buy" ratings from analysts. The question, though, is whether that should matter to investors.
Abiomed, Inc. , a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer
Months after federal regulators warned doctors that one of the heart pumps made by Danvers’ Abiomed could be linked to a higher rate of death than previously thought, the company’s device has been cleared by the FDA.
The Standard & Poor's 500 index—commonly called the S&P 500, or simply the S&P—is the primary gauge of the large-cap U.S. equities market. It is based on the market capitalization figures of the top 500 companies that list their common stock on the NYSE or NASDAQ. Based on available historical data, the S&P has generated an average annual return of around 9.8% from 1928 through 2016.
Use of early identification protocol leads to higher survival and native heart recovery, as demonstrated in FDA studies
Improves upon AMI cardiogenic shock historical survival of 50%
The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.
Abiomed announces today that the Impella CP with SmartAssist, which is designed to improve patient outcomes with advanced algorithms and simplified patient management, will be commercially available beginning at the 2019 Society for Cardiovascular Angiography & Interventions Scientific Sessions through a controlled launch process at select sites.
Abiomed (ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The Impella 5.0 and the Impella LD are forward flow heart pumps that deliver up to 5 L/min, stabilizing a patient’s hemodynamics, unloading the left ventricle, and perfusing the end organs, allowing for the potential of native heart recovery or return to heart function baseline. The Impella 5.0 is implanted through the femoral or axillary artery and the Impella LD is implanted directly into the aorta.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
These two med-tech companies failed to impress investors in the first quarter. Is the bull case for owning these stocks still intact?
The medical device maker's first earnings report as a public company featured explosive revenue growth and upbeat full-year guidance.